SynthesisFrontiers in neurology2026
Melatonin supplementation in multiple sclerosis: a systematic review of clinical, imaging, biomarker, and safety outcomes.
Synthesis in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Melatonin may act on immune, oxidative, and circadian pathways relevant to multiple sclerosis (MS), yet its clinical benefits and safety profile remain unclear. This systematic review assessed the efficacy and safety of oral melatonin supplementation in adults with MS. Methods: We searched MEDLINE (via PubMed), Scopus, Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception through August 15, 2026, and included randomized and prospective non-randomized intervention studies. Two reviewers independently selected studies, extracted data, and assessed risk of bias using RoB 2 or ROBINS-I. Given substantial clinical and methodological heterogeneity, we synthesized findings without meta-analysis, following SWiM guidance, and rated certainty of evidence with GRADE. We registered the protocol in PROSPERO (CRD420251167112). Results: We included 10 independent studies, reported across 17 publications, covering 435 participants. Nine were randomized trials (two of them crossover designs), and one was a prospective non-randomized intervention study. Melatonin doses spanned 0.5-300 mg/day, with treatment durations from 2 weeks to 14 months. The evidence did not show reductions in relapse activity, disability progression, or new MRI activity. Small studies suggested possible improvements in sleep, fatigue, pain, physical function, cognition, mood, autonomic function, body composition, and inflammatory, metabolic, or oxidative-stress biomarkers, but these results were inconsistent and rarely replicated. Doses of 0.5-25 mg/day were generally well tolerated, though some participants discontinued treatment and adverse-event reporting remained incomplete. At 300 mg/day, three of four melatonin-treated participants developed hypertransaminasemia, which resolved after withdrawal and recurred on rechallenge in one case. Certainty of evidence was low or very low for every outcome assessed. Conclusion: Current evidence does not support a disease-modifying effect of melatonin in MS. Any symptomatic or biomarker benefits need confirmation in larger, well-designed trials, and high-dose melatonin may carry meaningful hepatic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.